Contains Fusidic Acid 2% w/w. Methyl Hydroxybenzoate 0.18% w/w and Propyl Hydroxybenzoate 0.02% w/w as preservatives.
Excipients/Inactive Ingredients: Cetostearyl Alcohol, Liquid Paraffin, Macrogol Cetostearyl Ether, Methyl Hydroxybenzoate, Propyl Hydroxybenzoate, Citric Acid Anhydrous, Sodium Citrate, Butylated Hydroxyanisole and Purified Water.
Pharmacology: Pharmacodynamics: Fusidic acid is a steroidal antibacterial with a bacteriostatic or bactericidal activity, mainly against Gram-positive bacteria. Fusidic acid inhibits bacterial protein synthesis although, in contrast to drugs such as macrolides or tetracyclines, it does not bind to the bacterial ribosome, but inhibits a factor necessary for translocation of peptide subunits and elongation of the peptide chain. It is capable of inhibiting protein synthesis in mammalian cells but exerts a selective action against susceptible infecting organisms because of poor penetration into the host cell. Fusidic acid is very active against staphylococci, notably Staph. aureus and Staph. epidermidis (including meticillin-resistant strains). Nocardia asteroides and many clostridial strains are also highly susceptible. The streptococci and enterococci are less susceptible. Most Gram-negative bacteria are intrinsically resistant but fusidic acid is active against Neisseria spp. and Bacteroides fragilis. It has some activity against strains of Mycobacterium tuberculosis and is highly active against M. leprae.
Pharmacokinetics: Fusidate is widely distributed into tissues and body fluids, including bone, pus and synovial fluid. It penetrates cerebral abscesses but does not enter CSF in appreciable amounts. It has been found in the fetal circulation and in breast milk. About 95% or more of fusidate in the circulation is bound to plasma proteins. Fusidate has a plasma half-life of about 10 to 15 hours. It is excreted in the bile, almost entirely as metabolites, some of which have weak antimicrobial activity. About 2% appears unchanged in the faeces. Little is excreted in the urine or removed by haemodialysis.
Defuzin cream is indicated for local treatment of skin infections, especially staphylococcal skin infections and penicillin resistant staphylococccal infections. Acute impetigo on small areas of the skin may be treated by short-term topical application of fusidic acid.
Apply as directed by the physician.
Apply 3-4 times daily.
Overdose in unlikely to occur. Unless hypersensitivity to fusidic acid or any other excipient exists, accidental ingestion of fusidic acid is unlikely to cause any harm.
Known hypersensitivity to fusidic acid or any other ingredients in Defuzin cream.
To minimise the development of resistant organisms, it is advisable to limit the choice of antibacterials applied topically to those not used systemically.
Topical antibacterials should be avoided on leg ulcers unless used in short courses for defined infections. Treatment of bacterial colonisation is generally inappropriate.
Use in pregnancy and during lactation should be considered only when the possible benefits outweigh the potential risks.
Hypersensitivity reactions in the form of rashes and irritation may occur with topical fusidates.
No drug interaction has been identified for topical preparation.
D06AX01 - fusidic acid ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.
Cream (tube) (white, smooth, homogenous) 2% w/w x 15 g.